Immunotherapy using antibodies that bind programmed death ligand-1 (PD-L1)

US11332531B2 · kind B2 · utility

Assignee

• REMD Biotherapeutics, Inc. · US

Inventors

• Frank J. Calzone · Westlake Village, US
• Hai Yan · Chapel Hill, US
• John Zhang · New York, US

Key dates

• Filing date: Dec 23, 2017
• Grant date: May 17, 2022
• Expiry date: Nov 27, 2038

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/92
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

This application provides isolated antibodies, and antigen-binding fragments thereof, that specifically bind Programmed Death Ligand-1 (PD-L1). These PD-L1 antibodies, or antigen-binding fragments thereof, have a high affinity for PD-L1, function to inhibit PD-L1, are less immunogenic compared to their unmodified parent antibodies in a given species (e.g., a human), are capable of increasing T-cell proliferation and IL-2 secretion in a mixed lymphocyte reaction, and can be used to treat human diseases (e.g., cancer, infectious diseases, autoimmune diseases, asthma, transplant rejection, and inflammatory disorders).